Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urinary Bladder Neoplasms 2 Glioblastoma 2 Stomach Neoplasms 1 Solitary Pulmonary Nodule 1 Non-Muscle Invasive Bladder Neoplasms 1 Multiple Pulmonary Nodules 1 Medication Adherence 1 Margins of Excision 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Glioma 1 Esophageal Neoplasms 1 Early-stage Peripheral Non-small Cell Lung Cancer 1 Dementia 1 Cognitive Dysfunction 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Brain Neoplasms 1 Alzheimer Disease 1

Interventions

pembrolizumab 243 Carboplatin 211 Pemetrexed 177 Cisplatin 131 Paclitaxel 113 Nivolumab 101 Docetaxel 87 osimertinib 85 durvalumab 78 Specimen Handling 56 atezolizumab 55 Gemcitabine 52 Drug Therapy 52 Magnetic Resonance Spectroscopy 50 Radiosurgery 48 Radiotherapy 47 Ipilimumab 41 130-nm albumin-bound paclitaxel 39 cemiplimab 38 Bevacizumab 34 Cetuximab 30 tislelizumab 29 amivantamab 22 Taxes 22 Platinum Compounds 20 Blood Specimen Collection 20 Immunotherapy 18 Immune Checkpoint Inhibitors 18 Radiation 17 Erlotinib Hydrochloride 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Non-Small-Cell Lung × Drug Delivery Systems × 1 year × Clear all

NCT06124118 2026-01-08

NOVOCURE

University of Utah

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡